This action might not be possible to undo. Are you sure you want to continue?
Presented by: Mr. NIMASE PRADEEP KISAN Research guide: PROF. DR. G. VIDYASAGAR
Veerayatan Institute Of Pharmacy, Kutch- Gujarat
. Improvement of drug bioavailability and reduction of the dosing frequency. Nanoparticles: submicron (< 1µm) colloidal particles.INTRODUCTION: Controlled drug delivery technology. Nanoparticles and microparticles. and may resolve the problem of non adherence to prescribed therapy. Macromolecules as carriers for the drugs.
erosion. natural. . The drug loaded in nanoparticles is usually released from the matrix by diffusion. or degradation. swelling. Polymers.e. i. synthetic or solid lipids and should be biocompatible and biodegradable.
Technological advantages of nanoparticles as drug carriers: High stability High carrier capacity Feasibility of incorporation of both hydrophilic and hydrophobic substances Feasibility of variable routes of administration .
LITERATURE REVIEW: Some sustained release nanoparticles identified. which are going to hit the market in near future. PRODUCT Rapamune Emend Tricor DRUG Sirolimus Aprepitatnt Fenofibrate Technology By Elan/Wyeth Elan/Merck Elan/Abbot SkyePharma/First Horizon Pharmaceuticals Triglide Fenofibrate .
which are under clinical trial for various applications: Product Genexol PM Estrasorb Medicelle Flucide Application Non-small cell lung cancer Estrogen therapy Cancer treatment Anti-influenza company Samyang Novavax NanoCarrier NanoViricides . Some of the products.
which is expected to rise to 70 million by the year 2025. Contributing factors: sedentary lifestyles. . improper sleep and deteriorating eating habits etc. According to the International Diabetes Federation report of 2006. high stress levels. Sustained release nanoparticles against diabetes Major lifestyle disease in India. there are around 41 million diabetics in India.
electro spray. nanofiltration.e. spray milling. Emulsification polymerization. ultracentrifugation. Preparation and evaluation of critical steps during formulation by choosing one among the various methods (i.PLAN OF WORK: Procurement and characterization of bulk drugs. Procurement and characterization of polymers.e.) . spray drying. mills. supercritical fluid technology. ultra sonicator. supercritical fluid technology. electro spray method) by utilizing various equipments for formulation (i. Homogenizer.
y y y In-vitro characterization of the formulation by taking various instruments.. In-vivo characterization of the drug would be tried against diabetes induced laboratory animals by following standard screening procedure. transmission electron microscopy) Stability study of some selected formulation as per ICH guidelines. zeta potential analyzer.PLAN OF WORK««. scanning electron microscopy. particle size analyzer.e. (i. .
FLOW CHART FOR METHOD OF PREPARATION & EVALUATION OF NANOPARTICLES NANOPARTICLES IN-VIVO SCREENING FOR ANTIDIABETIC ACTIVITY .
Nanoparticles. 83:373±378. Khuller GK. Tropical Journal of Pharmaceutical Research.J. R. Tiyaboonchai. Ken Donaldson. p.. Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Lang Tran.Y Chen.Soane. December 2008.4.C. Davis. Chitosan Nanoparticles: A Promising System for drug delivery. Zahoor A. Tuberculosis (Edinb) 2003.P.G.S. 4. . Rob Aitken.REFERENCES: 1. 2. 3. 7. Ain Q. Pandey R.K. 561):561-573. 11(3): 51-66.Int. A.Pandey H. Fintan Hurley.159-162.IIlim. 21st edition. M. Human effects of Nanoparticle Exposure. No.Mohammad. Jon Ayres.178(1999)5565. Khuller GK. Antioxidant properties of some nanoparticles may enhance wound healing in T2DM Patient.evaluation of the clearance characteristics of boiadhesive system in humans. Digest Journal of Nanomaterials and Biostructures Vol.A review.3.J. 6. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. N. S. Perkins. 239:37±46. Int J Pharm 2002. Mishra V. June.S. 8 . Sharma S.Pharm.Ferier.Jones. Naresuan University Journal 2003. Garg SK. 5.. W. V J Mohanraj. Sharma S. Remington Pharmaceutical Sciences. L.